Navigation Links
Gene Responsible for Blindness in Infants and Children Identified

Montreal, June 4, 2007 An international team led by MUHC has identified the gene that causes Leber Congenital Amaurosis (LCA). LCA is a common congenital blindness in infants and small children. The study has been published in todays issue of Nature Genetics and is partly funded by the Foundation Fighting Blindness in Canada (FFB-C).

This discovery has the potential to fast-track a cure for this disease, says lead investigator Dr. Robert Koenekoop, director of the McGill Ocular Genetics Centre at the MUHC. Our main research goal is to identify all the genes responsible for congenital blindness in children and then study them so that we can then use gene therapy to rescue their vision.

Working with an international team of researchers including Drs. Anneke den Hollander, Frans Cremers and Ronald Roepman from the University of Nijmegen in The Netherlands, and Dr. Chris Inglehearn from The University of Leeds in the UK, Dr. Koenekoop and his team, including Dr. Irma Lopez, used a new technique called SNP (single nucleotide polymorphism) technology to identify homozygous regions in the genome, which led to the discovery of the new gene called LCA5.

In the past, large families were necessary to find genes, but in this study only samples from one Quebec and one American patient were used to accomplish this. The SNP micro array technology accelerated the process of locating the gene and enabled the investigators to isolate it within a few months instead of several years. This method may become a model for identifying other retinal diseases and causes of blindness in the future, says Dr. Koenekoop, who is also associate professor in Ophthalmology and Human Genetics at McGill University.

The same international research team identified the CEP290 gene last year, the most common genetic cause of LCA (American Journal of Human Genetics September, 2006). By using the protein structure of CEP290, the investigators were abl e to discover LCA5, as they have similar structures and functions in the retina.

Both the CEP290 and LCA5 genes encode proteins with vital functions in the cilium of the photoreceptors, transporting visual proteins to the compartment where vision occurs. When these genes are mutated, which occurs in about 25 to 30 per cent of blind children, the visual proteins are not transported properly to the outer segments, causing the photoreceptors to stop working and die.

This year, after many years of research on a related LCA gene called RPE65 and a spectacular rescue of vision by RPE65 gene replacement in dogs with LCA, human clinical trials have started in London, UK and in Philadelphia, USA. Preliminary results have been very encouraging and we expect to launch clinical trials investigating gene replacement for CEP290 and LCA5 in the near future, says Dr. Koenekoop.

An estimated 200,000 children worldwide are afflicted with LCA. The FRSQ, the TD FINANCIAL GROUP and The Foundation Fighting Blindness in Canada (FFB-C) funded this research. Discoveries like this one show us that treatments and cures are in sight. The Foundation Fighting Blindness in Canada is proud to fund quality vision research at the MUCH that is giving hope to families affected by blindness, says Sharon Colle, National Executive Director of the FFB-C.


'"/>




Related medicine news :

1. PET Scan find the Area of Brain Responsible for Anorexia Nervosa
2. Arsenic May Have Been Responsible For The Madness Of King George III Of England
3. Gene That Might Be Responsible For Aging
4. Enzyme Responsible For Congenital Blindness
5. New Virus Held Responsible For Respiratory Infection In Children
6. Researchers Identify Sipa 1 Gene, Responsible For Cancer Metastasis
7. Nurse Held Responsible For Insulin Overdose
8. Coroner Says Sativex Is Responsible For Death Of Patient
9. Alcohol Is Responsible For 60 Different Diseases
10. Scientists Identify Gene Responsible For Depression
11. Genes That Were Responsible For The Cause Of Blindness Identified
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
Breaking Medicine Technology: